Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
BACKGROUND: Heterozygous activating mutations in KCNJ11, encoding the Kir6.2 subunit of the ATP-sensitive potassium (K(ATP)) channel, cause 30 to 58 percent of cases of diabetes diagnosed in patients under six months of age. Patients present with ketoacidosis or severe hyperglycemia and are treated...
Main Authors: | Pearson, E, Flechtner, I, Njølstad, P, Malecki, M, Flanagan, SE, Larkin, B, Ashcroft, F, Klimes, I, Codner, E, Iotova, V, Slingerland, A, Shield, J, Robert, J, Holst, J, Clark, P, Ellard, S, Søvik, O, Polak, M, Hattersley, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2006
|
Similar Items
-
Permanent neonatal diabetes caused by an in-frame deletion in the N-terminus of Kir6.2
by: Craig, T, et al.
Published: (2008) -
Interaction of the cytosolic domains of the Kir6.2 subunit of the K(ATP) channel is modulated by sulfonylureas.
by: Lippiat, J, et al.
Published: (2002) -
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
by: Sagen, J, et al.
Published: (2004) -
A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications.
by: Tammaro, P, et al.
Published: (2008) -
Interaction between mutations in the slide helix of Kir6.2 associated with neonatal diabetes and neurological symptoms.
by: Männikkö, R, et al.
Published: (2010)